Participated · Seed · Jan 2026

OutSee applies a “genomics-first” strategy to drug target discovery through its proprietary Nomaly platform, which employs hypothesis-free AI modelling to predict disease and phenotype directly from individual genomes. By analysing fundamental molecular and cellular biology, Nomaly is able to reveal disease-driving mechanisms even in small or previously analysed datasets, making it complementary to conventional target-discovery pipelines. The company is building an internal portfolio of data-backed targets and has already identified a lead candidate that will advance into drug discovery with support from external partners. A recent strategic collaboration with o2h discovery will create a library of drug candidates against this lead target, leveraging o2h’s integrated pre-clinical CRO capabilities and co-discovery InflexionTx match-funding model. Proceeds from OutSee’s oversubscribed £2.5 million seed round will fund experimental validation of additional targets, expansion of its in-house discovery programme, and continued R&D to evolve Nomaly from validation phase to active value generation. The financing also underscores growing investor confidence in the company’s AI-powered approach to precision medicine.